LITS
Lite Strategy, Inc.1.5200
-0.0100-0.65%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
55.91MP/E (TTM)
-Basic EPS (TTM)
-1.31Dividend Yield
0%Recent Filings
8-K
8-K
Switches auditors to CBIZ
8-K
File named permanent CEO
10-Q
Q1 FY2026 results
Lite Strategy narrowed its Q1 FY2026 net loss to $3.6M from $8.0M y/y, as operating expenses dropped to $3.7M from $8.4M amid lighter R&D and staff cuts—yet digital asset fair value dipped $0.6M. EPS improved to $(0.12) from $(1.20) on 29.5M weighted shares, matching basic/diluted with anti-dilution from nominal pre-funded warrants. July's $100M PIPE funded $100M LTC buy, leaving $10.1M cash and $99.4M digital assets at quarter-end; no debt. Cash burn hit $4.5M from ops, offset by $96.6M financing. Balance sheet bulks up. LTC volatility looms large.
8-K
$25M stock buyback authorized
Lite Strategy's board authorized a $25 million common stock repurchase program on October 29, 2025, effective immediately, to buy back shares opportunistically via open market or negotiated deals using working capital. This signals a pivot from initial Litecoin accumulation toward active capital market tactics, optimizing the company's nearly 1 million Litecoin treasury for stockholder value when shares trade at discounts to modified net asset value. The program offers flexibility but carries risks like Litecoin price fluctuations and potential impairment charges.
AIBT
Aibotics Inc.
0.00+0.00
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
IMA
ImageneBio, Inc.
6.25+0.08
INTI
Inhibitor Therapeutics Inc.
0.05-0.00
INTS
Intensity Therapeutics, Inc.
0.44+0.02
KTTA
Pasithea Therapeutics Corp.
1.14-0.02
LIMN
Liminatus Pharma, Inc.
0.78+0.02
LIXT
Lixte Biotechnology Holdings, I
4.10+0.11
LTRN
Lantern Pharma Inc.
3.33-0.04
MAIA
MAIA Biotechnology, Inc.
1.23-0.12